This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Kelly Moynihan, Ph.D.
Senior Director and Program Team Leader at Asher Biotherapeutics


Kelly D. Moynihan received a B.S. degree in biomedical engineering from the University of Texas followed by a Ph.D. in biological engineering from MIT in the lab of Darrell Irvine, where she was a Hertz Foundation Fellow, NSF Fellow, and Siebel Scholar. Kelly then worked in biotech company creation at Third Rock Ventures, where she contributed to the formation and launch of multiple immunology-focused biotech startups, including Celsius Therapeutics, Abata Therapeutics, and Asher Biotherapeutics. Kelly now works as a Senior Director and Program Team Leader for AB248 at Asher Biotherapeutics, a clinical-stage South San Francisco-based biotechnology company.

Agenda Sessions

  • Engineering Cell-type Selective Immunotherapies Via Cis-targeting